The Wegovy pill is an oral, once-daily version of semaglutide, the same active ingredient that the injection version has. It was approved in the UK by the MHRA on 11 June 2026. Literally the day on which this article is being written. 

But before you rush to the first source you find online to buy it, it’s important to know many things about it.

Spoiler: It doesn’t exactly work like the injection.

Infographic confirming the oral semaglutide 25mg Wegovy pill is MHRA approved in the UK, showing 16.6% average weight loss at 64 weeks, 1 in 3 men losing 20%+ of body weight, and male health benefits including visceral fat, testosterone, cardiovascular risk and metabolic syndrome.

‍

Let’s start from the basics -

So, What Exactly Is the Wegovy Pill?

The Wegovy pill is an oral tablet containing semaglutide, the same active ingredient that the injection has, which is a GLP-1 receptor agonist. GLP-1 is a hormone your gut naturally releases after you eat. It basically tells your brain that you're full, slows down digestion, and helps regulate blood sugar. Semaglutide simply goes and mimics that hormone but with more intensity.

The pill works on the same mechanism, just gets absorbed in your body differently. And that changes a lot of things.  

How is the Wegovy pill different from the injection?

The injection goes straight under your skin and into your bloodstream. Simple, direct, done once a week. No specific requirements for it to get absorbed in your body.

It’s different with the pill because semaglutide is a protein  and your stomach is designed to break proteins down. If you simply take the pill at a random time your stomach would destroy the medication before it ever reaches your bloodstream. So Novo Nordisk developed something called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) technology. It is a compound that acts as a shield in your stomach which allows semaglutide to absorb directly through the stomach lining before your gut acid gets to it.

But for SNAC to work, there are some terms and conditions:

  • You must take it first thing in the morning, before anything else
  • Only with a small glass of plain water (up to 120 ml). No coffee, no juice, not even sparkling water. 
  • And then strict fast for at least 30 minutes before eating, drinking, or taking other medications

You may think that the pill is too demanding, and difficult to adjust it in your routine. Honestly, it’ll only feel like that for the first week or two. After that it becomes automatic. Most men find it easier than remembering a weekly injection because it fits into an existing morning routine.

The pill has its own benefits - 

  • No refrigeration required.
  • Travel friendly
  • Great option for people facing a needle phobia

‍

But nothing matters more than the numbers. So here’s what they say -

What Do the Numbers Actually Say?

The approval of the pill  is based on the OASIS 4 trial, a phase 3 randomised controlled trial published in the New England Journal of Medicine.

Here's what they found at 64 weeks:

  • Average weight loss of 16.6% with full adherence (vs 2.7% with placebo)
  • 13.6% average loss even for people who didn’t stick to the full dose
  • 79.2% of participants on the pill lost at least 5% of body weight
  • 63% lost at least 10%
  • 30% lost 20% or more
  • Serious adverse events were less frequent in the semaglutide group (3.9%) than placebo (8.8%)

‍

Text infographic explaining that the Wegovy pill is not the same as Rybelsus — Rybelsus is oral semaglutide licensed for type 2 diabetes at doses up to 14mg, while the Wegovy pill is a different formulation approved for weight management.

‍

‍

More than Weight Loss

The Visceral Fat Problem

For men, the idea of weight is a bit different than for women. Most of the weight in a men’s body comes from visceral fat,  the fat stored around your organs: liver, heart, pancreas, intestines. You can't always see it. Some men may not even look overweight, but they can be carrying a lot of weight internally.

Visceral fat can be very harmful. It drives inflammation, insulin resistance, cardiovascular disease, and type 2 diabetes. And men, on average, carry more of it at any given BMI than women.

Here’s where GLP-1 medications help. Agonists like semaglutide are particularly effective at reducing visceral fat. Research published in the International Journal of Obesity found that semaglutide reduced visceral adipose tissue and improved the ratio of muscle mass to visceral fat. This matters far more than the number on the scales.

‍

Testosterone and Weight Loss

More body fat does not just affect how you look, but also your hormone profile directly. Fat cells contain an enzyme called aromatase, which converts testosterone to oestrogen. So, higher the fat, lower the testosterone levels in your body. And this affects your energy, muscle mass, mood, libido, and sleep. 

Research presented at the Endocrine Society's 2025 annual meeting found that men on GLP-1 medications like semaglutide, who achieved a 10% weight reduction saw testosterone levels increase by 53% to 77% over 18 months.

So, if you feel all of the things mentioned above, and think that it’s just age, you may want to think again.

‍

Cardiovascular Risk

Men tend to develop cardiovascular disease about 10 years earlier than women on average. Culprit? Obesity. Visceral obesity to be particular. The OASIS 4 trial data showed that participants achieving significant weight loss with oral semaglutide also saw improvements in systolic blood pressure, lipid profiles, and inflammatory markers.

The conversation just shifted from just your looks to  your heart, your arteries, and your metabolic baseline.

‍

Side Effects: What You're Likely to Experience

If you’ve tried or have known about the side effects of Mounjaro injection, you’ll feel familiar with these as well:

  • Nausea (usually improves after the first few weeks)
  • Constipation
  • Diarrhoea or loose stools
  • Reflux or heartburn
  • Reduced appetite (actually an effect more than a side effect)

‍

The good news: Based on clinical data, GI related side effects in men tend to be slightly less severe than in women on average. You’ll still have to go through an adjustment phase, but most men report things settling down after 4–6 weeks.

Now we know what you may be wondering: Can I have alcohol when I’m on weight loss medications?

Text infographic explaining that GLP-1 medications can amplify the effects of alcohol, that men who drink regularly may feel effects faster, and advising disclosure of cardiovascular medications to a clinician before starting treatment
What men should know about alcohol on a GLP-1 - stronger effects, appetite changes, and why to tell your clinician about cardiovascular medications first.

‍

Pill vs Injection: Which Is Right for You?

The pill won't replace the injection for everyone and not everyone should be thinking about switching as well. We’ve written the differences in lifestyle with both above. Some men will prefer the injection for exactly that reason.

Here's a quick comparison to help you get further clarity:

Comparison table of the Wegovy pill versus Wegovy injection covering frequency, how each is taken, refrigeration and fasting needs, UK approval, average weight loss, and HeMed pricing from £154 and £159 a month.
Wegovy pill vs injection compared - frequency, administration, weight loss results and pricing to help men choose the right option

‍

‍

‍

‍

‍

‍

‍

Frequently Asked Questions

Can I get the Wegovy pill in the UK right now?

The MHRA approved it on 11 June 2026. Novo Nordisk has said it expects the pill to be available via private prescription within weeks. NHS accessibility will take more time as NICE would need to conduct its own review before that happens.

Is the Wegovy pill the same as Rybelsus?

No. Both contain oral semaglutide, but Rybelsus is a lower-dose tablet (up to 14 mg) licensed in the UK for type 2 diabetes. The Wegovy pill is 25 mg and licensed specifically for weight management in adults with obesity or overweight and a weight-related health condition. 

Is oral semaglutide safe for men?

Clinical trial data shows a safety profile consistent with injectable semaglutide. Men in trials generally reported gastrointestinal side effects slightly less frequently than women. Common side effects include nausea, constipation, and reflux, particularly in the early dose-escalation weeks. 

Please note: Oral semaglutide is not recommended for men with or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome. Please disclose your full medication list, including cardiovascular drugs and alcohol intake, before starting.

Can GLP-1 medications affect testosterone levels?

Yes and in a good way for most men. Excess body fat increases aromatase activity, which converts testosterone to oestrogen and suppresses your natural testosterone levels. Research found that men who achieved 10% weight loss on GLP-1 medications saw testosterone levels increase by 53–77% over 18 months. 

What is the Wegovy pill dosing schedule?

It starts at 1.5 mg and escalates gradually over approximately 12 weeks up to the maintenance dose of 25 mg. Available doses are 1.5 mg, 4 mg, 9 mg, and 25 mg. 

How is the Wegovy pill different from the injection?

The pill is taken daily and the injection is weekly. Both have the same active ingredient. The pill requires a strict empty-stomach routine in the morning and no refrigeration. Average weight loss in trials is around 14–17% with the pill vs. up to 20.5% with the highest-dose injection. 

Will the NHS prescribe the Wegovy pill?

Not initially. NHS prescribing requires a separate NICE technology appraisal. Given that the Wegovy injection received a restricted NICE recommendation in 2023, limiting NHS prescribing to specialist weight management services, oral semaglutide (the pill) is likely to follow a similar path.

‍

Sources

1. Novo Nordisk — Wegovy pill MHRA approval announcement, 11 June 2026. GlobeNewswire / BioSpace.

2. Garvey WT et al. — OASIS 4 Phase 3 trial (NCT05564117). New England Journal of Medicine, September 2025.

3. American College of Cardiology — OASIS 4 analysis: oral semaglutide 25 mg vs. placebo. September 2025.

4. Applied Clinical Trials — FDA approves oral Wegovy; OASIS 4 cardiometabolic data, 2025–2026.

5. Portillo Canales S et al. — GLP-1 medications and testosterone in men with obesity. Endocrine Society Annual Meeting, 2025. Reported by Pharmacy Times.

6. International Journal of Obesity — GLP-1 agonists, body composition, and visceral adipose tissue meta-analysis, April 2026.

7. MHRA — Medicines and Healthcare products Regulatory Agency. gov.uk/mhra.

8. NICE — National Institute for Health and Care Excellence guidance on weight management.

  1. PMC

10. Endocrine

‍

HeMed is a clinically-led, UK-based weight management programme. All clinicians are UK-registered. Pharmacy partner: eMed Healthcare UK (GPhC-registered, CQC-regulated). This article is for information only and does not constitute medical advice. Always consult a qualified clinician before starting any treatment.

‍